Pluristem Therapeutics, Inc. (PSTI) Earns Buy Rating from Seaport Global Securities

Seaport Global Securities reissued their buy rating on shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a research report released on Friday, MarketBeat Ratings reports. The brokerage currently has a $5.00 price objective on the biotechnology company’s stock. Seaport Global Securities also issued estimates for Pluristem Therapeutics’ Q3 2018 earnings at ($0.09) EPS.

PSTI has been the topic of several other research reports. Maxim Group upgraded Pluristem Therapeutics from a hold rating to a buy rating and set a $2.00 target price on the stock in a report on Monday, June 19th. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the stock a buy rating in a report on Thursday, August 17th. ValuEngine upgraded Pluristem Therapeutics from a strong sell rating to a sell rating in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered Pluristem Therapeutics from a hold rating to a sell rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Pluristem Therapeutics has an average rating of Hold and a consensus price target of $4.13.

Pluristem Therapeutics (PSTI) opened at 1.49 on Friday. The firm’s market cap is $145.23 million. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $1.65. The stock’s 50 day moving average price is $1.34 and its 200-day moving average price is $1.31.

ILLEGAL ACTIVITY NOTICE: “Pluristem Therapeutics, Inc. (PSTI) Earns Buy Rating from Seaport Global Securities” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/09/pluristem-therapeutics-inc-psti-earns-buy-rating-from-seaport-global-securities.html.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% during the first quarter, according to the company in its most recent Form 13F

PSTI has been the topic of several other research reports. Maxim Group upgraded Pluristem Therapeutics from a hold rating to a buy rating and set a $2.00 target price on the stock in a report on Monday, June 19th. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the stock a buy rating in a report on Thursday, August 17th. ValuEngine upgraded Pluristem Therapeutics from a strong sell rating to a sell rating in a report on Monday, October 2nd. Finally, Zacks Investment Research lowered Pluristem Therapeutics from a hold rating to a sell rating in a report on Friday, September 22nd. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Pluristem Therapeutics has an average rating of Hold and a consensus price target of $4.13.

Pluristem Therapeutics (PSTI) opened at 1.49 on Friday. The firm’s market cap is $145.23 million. Pluristem Therapeutics has a one year low of $1.04 and a one year high of $1.65. The stock’s 50 day moving average price is $1.34 and its 200-day moving average price is $1.31.

ILLEGAL ACTIVITY NOTICE: “Pluristem Therapeutics, Inc. (PSTI) Earns Buy Rating from Seaport Global Securities” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://ledgergazette.com/2017/10/09/pluristem-therapeutics-inc-psti-earns-buy-rating-from-seaport-global-securities.html.

An institutional investor recently raised its position in Pluristem Therapeutics stock. Renaissance Technologies LLC boosted its holdings in shares of Pluristem Therapeutics, Inc. (NASDAQ:PSTI) by 9.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,553,800 shares of the biotechnology company’s stock after buying an additional 129,000 shares during the quarter. Renaissance Technologies LLC owned approximately 1.62% of Pluristem Therapeutics worth $1,911,000 at the end of the most recent reporting period. 4.47% of the stock is currently owned by hedge funds and other institutional investors.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply